Clinical, pathological and prognostic implications of USP22, SIRT1 and E-cadherin expression in papillary thyroid cancer (PTC) and adjacent non-neoplastic tissue
Authors:
- Ola A. HarbOHOla A. Harb
- Randa Mohamed KafRKRanda Mohamed Kaf
- Heba F. TahaHTHeba F. Taha
- Safa A. BalataSBSafa A. Balata
- Rehab HemedaRHRehab Hemeda
- Ahmed Mohamed YehiaAYAhmed Mohamed Yehia
- Loay M. GertallahLGLoay M. Gertallah
- Ahmed EmbabyAEAhmed Embaby
Open Access
- 16 August 2019
- journal article
- Published by Springer Nature in Surgical and Experimental Pathology
- Vol. 2 (1)
Abstract
Introduction: Ubiquitin-specific peptidase 22 (USP22) is described as a stem cell (CSC) marker which is involved in many biological processes, including cancer development, cellular growth and differentiation. Sirtuin 1 (SIRT1) controls a set of biologic processes that range from metabolic homeostasis to cancer. E-cadherin is a calcium-dependent intercellular adhesion molecule. Clinically, USP22, SIRT1 and E-cadherin have been studied to predict prognosis of a variety of cancers but the detailed roles of their expression in papillary thyroid cancer (PTC) and their relation to cancer invasion, metastases and recurrence are still not fully explained. Aim of the study: To evaluate the expression of USP22, SIRT1 & E-cadherin in PTC tissues and adjacent non-neoplastic thyroid tissue and to correlate their expression with histopathology, clinical, pathological and prognostic parameters of PTC patients. Methods: We have assessed USP22, SIRT1 & E-cadherin expression using immunohistochemistry in 40 cases with PTC in both malignant tissue and adjacent non-neoplastic tissue, analyzed the relationships between their levels of expression, clinic-pathological parameters, prognosis and survival of patients. Results: High protein expression levels of both USP22, SIRT1 in addition to low E-cadherin expression in PTC were associated with larger tumors, extra-thyroidal extension, vascular invasion, lymphatic spread (p < 0.001), existence of distant metastases (p = 0.005 & 0.012 respectively), higher stage of the disease (p = 0.012 & 0.042 respectively) and worse five-years overall survival rates (p < 0.001). Conclusion: Patients having advanced PTC with unfavorable prognosis had high levels of both USP22, SIRT1 in addition to low E-cadherin expression.Keywords
This publication has 44 references indexed in Scilit:
- Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with ImatinibCancer Cell, 2012
- SIRT1 Is Essential for Oncogenic Signaling by Estrogen/Estrogen Receptor α in Breast CancerCancer Research, 2011
- The basics of epithelial-mesenchymal transitionJournal of Clinical Investigation, 2009
- Impaired DNA Damage Response, Genome Instability, and Tumorigenesis in SIRT1 Mutant MiceCancer Cell, 2008
- Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal TransitionPLOS ONE, 2008
- Loss of E-Cadherin Promotes Metastasis via Multiple Downstream Transcriptional PathwaysCancer Research, 2008
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumorsNature Genetics, 2008
- The SIRT1 Deacetylase Suppresses Intestinal Tumorigenesis and Colon Cancer GrowthPLOS ONE, 2008
- Inhibition of SIRT1 Reactivates Silenced Cancer Genes without Loss of Promoter DNA HypermethylationPLOS Genetics, 2006